



and kinetics of response with ipilimumab. *J Clin Oncol*. 2012;30(21):2691-2697.

21. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med*. 2012;366(26):2443-2454.

22. Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. *Ann Oncol*. 2017;8(10):2377-2385.

23. Berner F, Bomze D, Diem S, et al. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. *JAMA Oncol*. 2019;5(7):1043-1047.

24. Willemsen M, Melief CJM, Bekkenk MW, and Luiten RM. Targeting the PD-1/PD-L1 Axis in Human Vitiligo. *Front Immunol*. 2020;11:579022.

25. Lebbé C, Meyer N, Mortier L, et al. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. *J Clin Oncol*. 2019;37(11):867-875.

26. Hommes JW, Verheijden RJ, Suijkerbuijk KPM, Hamann D. Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events-A Comprehensive Review. *Front Oncol*. 2020;10:585311.

27. Teulings HE, Limpens J, Jansen SN, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. *J Clin Oncol*. 2015;33(7):773-781.

28. Fujisawa Y, Yoshino K, Otsuka A, et al. Retrospective study of advanced melanoma pa-

tients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients. *J Dermatol Sci*. 2018;89(1):60-66.

29. Weber JS, Hodi FS, Wolchok JD, et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. *J Clin Oncol*. 2017;35(7):785-792.

30. Haratani K, Hayashi H, Chiba Y, et al. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. *JAMA Oncol*. 2018;4(3):374-378.

31. Ishihara H, Takagi T, Kondo T, et al. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. *Urol Oncol*. 2019;37(6):355.e21-355.e29.

32. Xing P, Zhang F, Wang G, et al. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. *J Immunother Cancer*. 2019;7(1):341.

33. Fiala O, Sorejs O, Sustr J, et al. Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors. *Anticancer Res* 2020;40(3):1219-1227.

34. Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. *Lancet Oncol*. 2017;18(5):611-622.

35. Agrawal S, Feng Y, Roy A, et al. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. *Journal for immunotherapy of cancer*. 2016;4:72-72.